NCT03687736View on ClinicalTrials.gov

Subject Satisfaction With AbobutulinumtoxinA Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 2, 2018

Primary Completion Date

November 7, 2019

Study Completion Date

December 4, 2019

Conditions
Glabellar Frown Lines
Interventions
BIOLOGICAL

AbobotulinumtoxinA

AbobotulinumtoxinA treatment in the glabellar region at Baseline and Month 6

Trial Locations (6)

60654

Galderma Study Site, Chicago

68144

Galderma Study Site, Omaha

80111

Galderma Study Site, Greenwood Village

90025

Galderma Study Site, Los Angeles

90404

Galderma Study Site, Santa Monica

94115

Galderma Study Site, San Francisco

Sponsors

Lead Sponsor

Galderma R&D
All Listed Sponsors
lead

Galderma R&D

INDUSTRY

NCT03687736 - Subject Satisfaction With AbobutulinumtoxinA Treatment | Biotech Hunter | Biotech Hunter